NFKB1 and colitis: This beneficial effect was reported to be mediated through the inhibition of TLR4-NF-κB-NLRP3 axis and, consistently, the pro-inflammatory cytokines (tumoral necrosis factor-α (TNF-α), IL-1β, IL-6, IL-2) levels were also suppressed in the treated colitis mice.